{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:51:29Z","timestamp":1794855089782,"version":"4.9.1"},"reference-count":98,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Frontline therapy for systemic amyloid light chain (AL) amyloidosis has evolved significantly with the approval of daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone, which has significantly improved rates of both hematologic and organ responses. Despite these advances, many patients eventually relapse, and there remains no established standard salvage regimen or optimal timing. In this review, we examine optimal timing of salvage regimens and currently available therapeutic options after daratumumab failure, including next-generation proteosome inhibitors or immunomodulatory drugs, autologous stem cell transplant, BCL-2 inhibitors, and emerging immunotherapeutic agents such as chimeric antigen receptor T-cell therapy and bispecific antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019223","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:53:49Z","timestamp":1774644829000},"page":"3799-3810","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Management of relapsed\/refractory AL amyloidosis"],"prefix":"10.1182","volume":"10","author":[{"given":"Jessica","family":"Ling","sequence":"first","affiliation":[{"name":"1Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia"},{"name":"2Department of Haematology, Sir Charles Gardiner Hospital, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hasib","family":"Sidiqi","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia"},{"name":"3Curtin Medical School, Curtin University, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"1","key":"2026060911321764700_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"2026060911321764700_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2024-205077","article-title":"Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026060911321764700_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"issue":"36","key":"2026060911321764700_bib4","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026060911321764700_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"issue":"1","key":"2026060911321764700_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/hemato3010008","article-title":"Monitoring patients with light chain (AL) amyloidosis during and after therapy: response assessment and identification of relapse","volume":"3","author":"Milani","year":"2022","journal-title":"Hemato"},{"issue":"5","key":"2026060911321764700_bib5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026060911321764700_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"key":"2026060911321764700_bib7","doi-asserted-by":"crossref","first-page":"101228","DOI":"10.1016\/j.blre.2024.101228","article-title":"Autologous stem cell transplantation in AL amyloidosis: muddy waters","volume":"68","author":"Hagen","year":"2024","journal-title":"Blood Rev"},{"issue":"7","key":"2026060911321764700_bib8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026060911321764700_bib9","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10","key":"2026060911321764700_bib10","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"2026060911321764700_bib11","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2026060911321764700_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060911321764700_bib32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026060911321764700_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bjh.19529","article-title":"Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed\/refractory light chain amyloidosis (AL) after initial bortezomib-based regime","volume":"205","author":"Bomsztyk","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026060911321764700_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib\u2013dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2026060911321764700_bib36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bjh.16401","article-title":"Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis","volume":"189","author":"Cohen","year":"2020","journal-title":"Br J Haematol"},{"issue":"18","key":"2026060911321764700_bib39","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2026060911321764700_bib40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2026060911321764700_bib41","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026060911321764700_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026060911321764700_bib47","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2024-208341","article-title":"Isatuximab in relapsed AL amyloidosis: results of a prospective phase II trial (SWOG S1702)","volume":"144","author":"Parker","year":"2024  5","journal-title":"Blood"},{"issue":"21","key":"2026060911321764700_bib56","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026060911321764700_bib57","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2026060911321764700_bib53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjh.12973","article-title":"Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens","volume":"166","author":"Mahmood","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2026060911321764700_bib54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/13506129.2018.1540410","article-title":"Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis","volume":"25","author":"Kastritis","year":"2018","journal-title":"Amyloid"},{"issue":"2","key":"2026060911321764700_bib55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjh.17685","article-title":"Lenalidomide and dexamethasone in relapsed\/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up","volume":"195","author":"Basset","year":"2021","journal-title":"Br J Haematol"},{"issue":"23","key":"2026060911321764700_bib63","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2026060911321764700_bib64","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2026060911321764700_bib61","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026060911321764700_bib62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/13506129.2020.1767566","article-title":"Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients","volume":"27","author":"Milani","year":"2020","journal-title":"Amyloid"},{"issue":"2","key":"2026060911321764700_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026060911321764700_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026060911321764700_bib67","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.17380","article-title":"Venetoclax induces profound and sustained responses in patients with relapsed\/refractory light-chain amyloidosis","volume":"193","author":"Pasquer","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2026060911321764700_bib66","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3390\/cancers15061710","article-title":"Venetoclax in relapse\/refractory AL amyloidosis\u2014a multicenter international retrospective real-world study","volume":"15","author":"Lebel","year":"2023","journal-title":"Cancers"},{"issue":"S2","key":"2026060911321764700_bib69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.HS9.0000936096.74708.86","article-title":"B01 venetoclax targeted therapy in AL amyloidosis patients: a retrospective analysis from the French Amyloidosis Network","volume":"7","author":"Roussel","year":"2023","journal-title":"HemaSphere"},{"issue":"10","key":"2026060911321764700_bib72","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1007\/s00277-024-05901-x","article-title":"Three years follow-up of venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression","volume":"103","author":"Rieger","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"2026060911321764700_bib71","first-page":"195","article-title":"Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy","volume":"31","author":"Dima","year":"2024","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"suppl 1","key":"2026060911321764700_bib70","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/blood-2024-203780","article-title":"Outcomes of venetoclax in patients with relapsed or refractory AL amyloidosis","volume":"144","author":"Theodorakakou","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026060911321764700_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00432-024-05733-2","article-title":"Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"2026060911321764700_bib16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026060911321764700_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"15","key":"2026060911321764700_bib18","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026060911321764700_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-021-00510-7","article-title":"Impact of early response on outcomes in AL amyloidosis following treatment with frontline bortezomib","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026060911321764700_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2020.1798224","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"issue":"18","key":"2026060911321764700_bib21","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood.2022016348","article-title":"Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival","volume":"140","author":"Basset","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026060911321764700_bib22","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2026060911321764700_bib23","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/bjh.19766","article-title":"Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis","volume":"205","author":"Staron","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"2026060911321764700_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","article-title":"When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression","volume":"3","author":"Palladini","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2026060911321764700_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/bloodadvances.2018021261","article-title":"Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details","volume":"3","author":"Sanchorawala","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"2026060911321764700_bib26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2017-06-788729","article-title":"Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation","volume":"130","author":"Browning","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026060911321764700_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026060911321764700_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"issue":"2","key":"2026060911321764700_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13506129.2025.2463678","article-title":"Supportive care for systemic amyloidosis","volume":"32","author":"Muchtar","year":"2025","journal-title":"Amyloid"},{"issue":"10","key":"2026060911321764700_bib30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.12136","article-title":"Bortezomib in the treatment of AL amyloidosis: targeted therapy?","volume":"92","author":"Sitia","year":"2007","journal-title":"Haematologica"},{"issue":"19","key":"2026060911321764700_bib33","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2026060911321764700_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2026060911321764700_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/13506129.2023.2169124","article-title":"A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed\/refractory systemic immunoglobulin light chain amyloidosis","volume":"30","author":"Ravichandran","year":"2023","journal-title":"Amyloid"},{"issue":"3","key":"2026060911321764700_bib43","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2026060911321764700_bib44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.25828","article-title":"High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate","volume":"95","author":"Milani","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"2026060911321764700_bib45","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","article-title":"Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures","volume":"38","author":"Zanwar","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026060911321764700_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cells10030545","article-title":"Daratumumab in the treatment of light-chain (AL) amyloidosis","volume":"10","author":"Palladini","year":"2021","journal-title":"Cells"},{"issue":"suppl 1","key":"2026060911321764700_bib48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2024-204700","article-title":"Efficacy and safety of isatuximab, pomalidomide and dexamethasone in relapsed AL amyloidosis: interim results of the Isamyp Phase 2 Joint Study from the IFM and ALLG","volume":"144","author":"Mollee","year":"2024","journal-title":"Blood"},{"key":"2026060911321764700_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","article-title":"Immunomodulatory drugs in AL amyloidosis","volume":"99","author":"Jelinek","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2026060911321764700_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2026060911321764700_bib51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2026060911321764700_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"issue":"3","key":"2026060911321764700_bib58","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.18234","article-title":"Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma","volume":"198","author":"Kawano","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"2026060911321764700_bib59","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.26191","article-title":"Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21","volume":"96","author":"Kimmich","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"2026060911321764700_bib60","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11912-024-01561-2","article-title":"Options for rescue treatment of patients with AL amyloidosis exposed to upfront daratumumab","volume":"26","author":"Bellofiore","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"suppl 1","key":"2026060911321764700_bib65","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2023-191133","article-title":"Daratumumab, pomalidomide and dexamethasone (DPd) in relapsed\/refractory light chain amyloidosis previously exposed to daratumumab","volume":"142","author":"Rosenbaum","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2026060911321764700_bib73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"suppl 1","key":"2026060911321764700_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/13506129.2011.574354047","article-title":"High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution","volume":"18","author":"Seldin","year":"2011","journal-title":"Amyloid"},{"issue":"10","key":"2026060911321764700_bib75","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol"},{"issue":"13","key":"2026060911321764700_bib76","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026060911321764700_bib77","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/cncr.30051","article-title":"Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis","volume":"122","author":"Gertz","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"2026060911321764700_bib78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"32","key":"2026060911321764700_bib79","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D\u2019Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026060911321764700_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"issue":"16","key":"2026060911321764700_bib81","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/bloodadvances.2025016586","article-title":"From CyBorD to Dara-CyBorD: ASCT utilization trends in AL amyloidosis, a 15-year analysis","volume":"9","author":"Muchtar","year":"2025","journal-title":"Blood Adv"},{"issue":"17","key":"2026060911321764700_bib82","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/bloodadvances.2020002219","article-title":"Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis","volume":"4","author":"Basset","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026060911321764700_bib83","first-page":"589.e1","article-title":"Second stem cell transplantation for relapsed refractory light chain (AL) amyloidosis","volume":"27","author":"Muchtar","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026060911321764700_bib86","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/bjh.19286","article-title":"Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"204","author":"Khwaja","year":"2024","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026060911321764700_bib87","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2024-203254","article-title":"Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: an updated analysis of a phase 2 study by the European Myeloma Network","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2026060911321764700_bib88","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and safety of anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","volume":"43","author":"Lebel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026060911321764700_bib89","article-title":"First 20-patient safety and efficacy data from nexicart-2, the first U.S. trial of CAR-T in R\/R light chain (AL) amyloidosis, nxc-201","volume":"146","author":"Landau","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026060911321764700_bib90","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ejh.14293","article-title":"Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma and concurrent light chain amyloidosis","volume":"113","author":"Goel","year":"2024","journal-title":"Eur J Haematol"},{"issue":"16","key":"2026060911321764700_bib91","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2025028383","article-title":"Safety and efficacy of elranatamab in patients with relapsed and\/or refractory immunoglobulin light-chain amyloidosis","volume":"146","author":"Vianna","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026060911321764700_bib92","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","article-title":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026060911321764700_bib93","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jha2.772","article-title":"First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma","volume":"4","author":"Leung","year":"2023","journal-title":"EJHaem"},{"issue":"8","key":"2026060911321764700_bib94","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026060911321764700_bib95","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.14348","article-title":"Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis","volume":"114","author":"Stalker","year":"2025","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2026060911321764700_bib96","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2025-692","article-title":"Phase 1\/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood"},{"issue":"14","key":"2026060911321764700_bib97","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026060911321764700_bib98","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cardfail.2023.10.277","article-title":"Safety and tolerability of Cael-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study","volume":"30","author":"Valent","year":"2024","journal-title":"J Card Fail"},{"issue":"19","key":"2026060911321764700_bib99","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1182\/bloodadvances.2025016731","article-title":"Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101","volume":"9","author":"Hughes","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026060911321764700_bib100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2025-693","article-title":"Renal responses in a phase 1\/2 study of at-02, a novel pan-amyloid depleter Ig fusion protein for the treatment of patients with AL amyloidosis","volume":"146","author":"Bell","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3799\/2523416\/blooda_adv-2025-019223-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3799\/2523416\/blooda_adv-2025-019223-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:33Z","timestamp":1781019153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3799\/567464\/Management-of-relapsed-refractory-AL-amyloidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":98,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019223","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,27]]}}}